Invion Partners with SANGMYUNG for Eye Disease Treatment
Key points
- Expanding Photosoft Platform for Eye Diseases
- SANGMYUNG to Fund Preclinical Studies
- Potential for New Treatment Options for Wet AMD
Full summary
Invion Limited (ASX: IVX) has entered into a collaboration with SANGMYUNG Innovation to evaluate the Photosoft platform technology for treating retinal vascular diseases, including wet age-related macular degeneration (wet AMD). SANGMYUNG will fund and conduct preclinical studies using Invion's Photosoft compounds, while Invion retains all rights to the technology. This partnership marks Invion's first in the ophthalmology sector, aiming to address the significant unmet need for new treatments in wet AMD, a leading cause of blindness. The global wet AMD market is substantial and growing, driven by an aging population and the need for new therapies.
Guidance
null
Outlook
null
Summary generated by a large language model. Please interpret with care.